Synapse Open Synapse
Biology

Iambic CEO on taking an AI drug company public

BioPharma Dive · · 7 min read

Fresh off a $150 million IPO, Tom Miller spoke to BioPharma Dive about the roadshow process and how he sees AI’s role in drug development evolving.

Latest from BioPharma Dive